Suppr超能文献

通过抑制DNA拓扑异构酶II合成具有重要药理活性的萘醌及2-苄基胡桃醌的抗癌活性

Synthesis of pharmacologically important naphthoquinones and anticancer activity of 2-benzyllawsone through DNA topoisomerase-II inhibition.

作者信息

Kumar Balagani Sathish, Ravi Kusumoori, Verma Amit Kumar, Fatima Kaneez, Hasanain Mohammad, Singh Arjun, Sarkar Jayanta, Luqman Suaib, Chanda Debabrata, Negi Arvind S

机构信息

CSIR-Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP), Lucknow 226015, U.P., India.

CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, U.P., India.

出版信息

Bioorg Med Chem. 2017 Feb 15;25(4):1364-1373. doi: 10.1016/j.bmc.2016.12.043. Epub 2016 Dec 28.

Abstract

Naphthoquinones are naturally occurring biologically active entities. Practical de novo syntheses of three naphthoquinones i.e. lawsone (1), lapachol (2), and β-lapachone (3b) have been achieved from commercially available starting materials. The conversion of lapachol (2) to β-lapachone (3b) was achieved through p-TSA/Iodine/BF-etherate mediated regioselective cyclisation. Further, 2-alkyl and 2-benzyllawsone derivatives have been prepared as possible anticancer agents. Four derivatives exhibited significant anticancer activity and the best analogue i.e. compound 21a exhibited potential anticancer activity (IC=5.2μM) against FaDu cell line. Compound 21a induced apoptosis through activation of caspase pathway and exerted cell cycle arrest at S phase in FaDU cells. It also exhibited significant topoisomerase-II inhibition activity. Compound 21a was found to be safe in Swiss albino mice up to 1000mg/kg oral dose.

摘要

萘醌是天然存在的生物活性物质。已从市售起始原料实现了三种萘醌即紫铆因(1)、拉帕醇(2)和β-拉帕醌(3b)的实际从头合成。通过对甲苯磺酸/碘/三氟化硼乙醚络合物介导的区域选择性环化实现了拉帕醇(2)向β-拉帕醌(3b)的转化。此外,已制备了2-烷基和2-苄基紫铆因衍生物作为可能的抗癌剂。四种衍生物表现出显著的抗癌活性,最佳类似物即化合物21a对FaDu细胞系表现出潜在的抗癌活性(IC = 5.2μM)。化合物21a通过激活半胱天冬酶途径诱导细胞凋亡,并使FaDU细胞在S期发生细胞周期阻滞。它还表现出显著的拓扑异构酶-II抑制活性。发现化合物21a在瑞士白化小鼠中口服剂量高达1000mg/kg时是安全的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验